Regeneron (REGN), Sanofi (SNY) Report Plans to Restructure Antibody Collaboration for Kevzara (sarilumab) and Praluent (alirocumab)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
After-Hours Movers 12/09: (ASNA) (SFIX) (MDB) Higher; (SCYX) (LVGO) (REGN) Lower (more...)
December 9, 2019 5:30 PM ESTToday's After-Hours Movers
Ascena Retail Group (NASDAQ: ASNA) 27% HIGHER; reported Q1 EPS of $0.18, versus ($0.09) reported last year. Revenue for the quarter came in at $1.3 million, versus $1.34 million reported last year.
SCYNEXIS, Inc. (NASDAQ : SCYX) 18.6% LOWER; commenced an underwritten public offering of shares of its common stock and warrants. In addition, SCYNEXIS expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and warrants being offered on the same... More
Sanofi (SNY) to Stop Research in Diabetes, Cardiovascular Diseases, May Sell Regeneron (REGN) Stake - Reports
December 9, 2019 4:37 PM ESTSanofi (NASDAQ: SNY) to Stop Research in Diabetes, Cardiovascular Diseases, May Sell Regeneron (NASDAQ: REGN) Stake - Reports
... MoreRegeneron Pharma's (REGN) '5458 Efficacy is Early but Interesting, Credit Suisse Reiterates Neutral
December 9, 2019 7:13 AM ESTCredit Suisse analyst Evan Seigerman reiterated a Neutral rating on Regeneron Pharma (NASDAQ: REGN) but sees interesting drug activity with REGN5458 in Multiple Myeloma after attending the American Society of Hematology Meeting (ASH).
The analyst appears to be warming to the story stating "It is difficult for us to pick a winner (or winners), given varying maturities of data and... More
Regeneron (REGN) First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma
December 9, 2019 6:20 AM ESTRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma. BCMA (B-cell maturation antigen) is a protein that is typically over-expressed on multiple myeloma cells. REGN5458 is designed to bind to BCMA on multiple myeloma cells and the CD3 receptor on T-cells, bridging them together and activating T-cell killing... More
